Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment of early AD, binds with high affinity to soluble Aβ...

詳細記述

書誌詳細

主要な著者:	Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-05-01
シリーズ:	Alzheimer’s Research & Therapy
主題:	Alzheimer’s disease Lecanemab Safety ARIA
オンライン･アクセス:	https://doi.org/10.1186/s13195-024-01441-8
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!